Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Waga

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Internal Medicine (Tokyo, Japan)|May 1, 1994
Suppression of normal hematopoiesis in acute leukemia: effect of leukemic cells on bone marrow stromal cells and hematopoietic progenitor cellsM Aoyagi, S Furusawa, K Waga, et al.
International Journal of Hematology|April 1, 1996
Preferential inhibitory effect of soluble factor(s) in human bone marrow stromal cells on proliferation of K562 leukemia cells versus normal myeloid progenitor cellsA Aoyagi, M Aoyagi, K Waga, et al.
International Journal of Hematology|August 1, 1992
Comparative effects of G-CSF, GM-CSF and IL-3 on cytosine arabinoside- and daunorubicin-mediated cytotoxicity of acute myeloid leukemia cells and normal myeloid progenitorsK Waga, S Furusawa, S Nagashima, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|February 1, 1993
[Amylase-producing plasma cell dyscrasia. Genomic analysis in a case of intramuscular tumor formation and a review of the literature]K Hirota, K Waga, S Nagashima, et al.
International Journal of Hematology|June 19, 1998
Mature and immature myeloid cells decrease the granulocyte colony-stimulating factor level by absorption of granulocyte colony-stimulating factorK Saito, Y Nakamura, K Waga, et al.
Leukemia|January 1, 1995
Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot studyK Yamada, S Furusawa, K Saito, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|March 1, 1995
[Comparison of low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor to intermediate-dose cytosine arabinoside and mitoxantrone with or without etoposide in the treatment of relapsed acute myeloid leukemia]K Saito, S Furusawa, K Yamada, et al.
Cancer Research|August 17, 2001
Implication of tyrosine kinase receptor and steel factor in cell density-dependent growth in cervical cancers and leukemiasJ R Caceres-Cortes, J A Alvarado-Moreno, K Waga, et al.
International Journal of Hematology|June 10, 2000
Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformationK Saito, Y Nakamura, M Aoyagi, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Internal Medicine (Tokyo, Japan)|May 1, 1994
Suppression of normal hematopoiesis in acute leukemia: effect of leukemic cells on bone marrow stromal cells and hematopoietic progenitor cellsM Aoyagi, S Furusawa, K Waga, et al.
International Journal of Hematology|April 1, 1996
Preferential inhibitory effect of soluble factor(s) in human bone marrow stromal cells on proliferation of K562 leukemia cells versus normal myeloid progenitor cellsA Aoyagi, M Aoyagi, K Waga, et al.
International Journal of Hematology|August 1, 1992
Comparative effects of G-CSF, GM-CSF and IL-3 on cytosine arabinoside- and daunorubicin-mediated cytotoxicity of acute myeloid leukemia cells and normal myeloid progenitorsK Waga, S Furusawa, S Nagashima, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|February 1, 1993
[Amylase-producing plasma cell dyscrasia. Genomic analysis in a case of intramuscular tumor formation and a review of the literature]K Hirota, K Waga, S Nagashima, et al.
International Journal of Hematology|June 19, 1998
Mature and immature myeloid cells decrease the granulocyte colony-stimulating factor level by absorption of granulocyte colony-stimulating factorK Saito, Y Nakamura, K Waga, et al.
Leukemia|January 1, 1995
Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot studyK Yamada, S Furusawa, K Saito, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|March 1, 1995
[Comparison of low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor to intermediate-dose cytosine arabinoside and mitoxantrone with or without etoposide in the treatment of relapsed acute myeloid leukemia]K Saito, S Furusawa, K Yamada, et al.
Cancer Research|August 17, 2001
Implication of tyrosine kinase receptor and steel factor in cell density-dependent growth in cervical cancers and leukemiasJ R Caceres-Cortes, J A Alvarado-Moreno, K Waga, et al.
International Journal of Hematology|June 10, 2000
Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformationK Saito, Y Nakamura, M Aoyagi, et al.
Pageof 1